A Randomized, Double-blinded, Phase II Study of Maintenance Pembrolizumab Versus Placebo After First-Line Chemotherapy in Patients With Metastatic Urothelial Cancer: Hoosier Cancer Research Network GU14-182
Phase of Trial: Phase II
Latest Information Update: 09 Feb 2018
At a glance
- Drugs Pembrolizumab (Primary)
- Indications Urogenital cancer
- Focus Therapeutic Use
- 10 Jun 2017 Biomarkers information updated
- 16 Nov 2015 Planned End Date changed from 1 Aug 2019 to 1 Nov 2019 as reported by ClinicalTrials.gov.
- 16 Nov 2015 Planned primary completion date changed from 1 Aug 2018 to 1 Nov 2018 as reported by ClinicalTrials.gov.